VectivBio Holding AG announced positive interim data from the company’s ongoing Phase II STARS Nutrition study evaluating the safety, pharmacokinetics, and efficacy of apraglutide, an investigational new drug that is a next-generation, long-acting synthetic GLP-2 agonist, in adult patients with SBS-IF and CIC.
[VectivBio Holding AG]